Top-News

Citius Pharmaceuticals Aktie News

Aktie
WKN:  A40MD0 ISIN:  US17322U3068 US-Symbol:  CTXR Branche:  Pharmazeutika Land:  USA
1,20 $
-0,05 $
-4,00%
1,0306 € 19:33:35 Uhr
Depot/Watchlist
Marktkapitalisierung *
6,52 Mio. €
Streubesitz
76,16%
KGV
-
Index-Zuordnung
-

Citius Pharmaceuticals News

04.12.25 - PR Newswire
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim PR Newswire
01.12.25 - PR Newswire
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) PR Newswire
21.11.25 - PR Newswire
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration PR Newswire
21.10.25 - PR Newswire
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces the Closing of Registered Direct Offering of $6.0 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
21.10.25 - PR Newswire
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces a Registered Direct Offering of $6.0 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire
20.10.25 - PR Newswire
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch
Citius Oncology Signs U.S. Distribution Agreement with McKesson to Support LYMPHIR™ Commercial Launch PR Newswire
17.10.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences
Citius Pharmaceuticals and Citius Oncology to Participate in Upcoming October 2025 Conferences PR Newswire
16.10.25 - PR Newswire
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™
Citius Oncology Signs Exclusive Commercialization Agreement with EVERSANA to Support Planned Q4 2025 Launch of LYMPHIR™ PR Newswire
10.09.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
09.09.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement
Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement PR Newswire
22.08.25 - PR Newswire
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch PR Newswire
12.08.25 - PR Newswire
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update PR Newswire
17.07.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
Citius Oncology Announces Closing of $9.0 Million Public Offering PR Newswire
16.07.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Citius Oncology Announces Pricing of $9.0 Million Public Offering PR Newswire
15.07.25 - PR Newswire
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora PR Newswire
08.07.25 - PR Newswire
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire
17.06.25 - PR Newswire
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-​The-Market Under Nasdaq Rules PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +0,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »